It is of interest to note that various leukemia-driven oncogenes, such as IDH1/IDH2, TET2, PML-RARA, TCF3-HLF, and RUNX1-RUNXT1, or treatment with targeted agents directed against aberrant kinases, such as FLT3 and JAK1/2 inhibitors, have been linked to reduced DNA repair activity, a condition that renders leukemic blasts sensitive to PARP inhibitors [179]. Here, TET2 is linked to leukemia.